2,3-Dimethyl-6,7-dimethoxy-1,2,3,4-tetrahydro-isochinolin | 5884-23-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 2,3-Dimethyl-6,7-dimethoxy-1,2,3,4-tetrahydro-isochinolin
• 英文别名: 6,7-dimethoxy-2,3-dimethyl-1,2,3,4-tetrahydro-isoquinoline；6,7-Dimethoxy-2,3-dimethyl-1,2,3,4-tetrahydro-isochinolin；1,2,3,4-Tetrahydro-6,7-dimethoxy-2,3-dimethylisoquinoline；6,7-dimethoxy-2,3-dimethyl-3,4-dihydro-1H-isoquinoline
• CAS: 5884-23-1
• 化学式: C₁₃H₁₉NO₂
• 分子量: 221.299
• InChiKey: FPKSKXFZCSATTG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  21.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 硫酸 、 水 、 锌 作用下， 生成 2,3-Dimethyl-6,7-dimethoxy-1,2,3,4-tetrahydro-isochinolin
  参考文献：
  名称：

  3-Methyl-3,4-dihydroisoquinolines and 3-Methyl-1,2,3,4-tetrahydroisoquinolines¹

  摘要：

  DOI：

  10.1021/ja01859a050

文献信息

• Method for Augmenting B Cell Depletion
  申请人：Chan C. Andrew

  公开号：US20080075719A1

  公开（公告）日：2008-03-27

  The present invention provides methods of augmenting B cell depletion by promoting intravascular access of B cell subsets sequestered in lymphoid tissues rendering the B cells sensitive to killing mediated by the B cell depleting agent. One method of promoting intravascular access is by the use of integrin antagonists. Methods of treating B cell disorders by this approach is also provided.
• US7595399B2
  申请人：——

  公开号：US7595399B2

  公开（公告）日：2009-09-29
• [EN] 6-HALO-PYRAZOLO[1, 5-A]PYRIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR (MGLUR) MODULATORS<br/>[FR] 6-HALO-PYRAZOLO[1,5-A]PYRIDINES, LEUR MÉTHODE DE PRÉPARATION ET LEUR UTILISATION COMME MODULATEURS DES RÉCEPTEURS MÉTABOTROPIQUES DU GLUTAMATE (MGLUR)
  申请人：MERZ PHARMA GMBH & CO KGAA

  公开号：WO2009095253A1

  公开（公告）日：2009-08-06

  The invention relates to 6-halo-pyrazolo[1, 5-a] pyridines of formula (I) as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.